Eric B Schwartz
Overview
Explore the profile of Eric B Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeong A, Schwartz E, Roman A, McDevitt R, Oerline M, Henry E, et al.
JCO Oncol Pract
. 2021 Sep;
18(2):e284-e292.
PMID: 34491783
Purpose: Abiraterone and enzalutamide are commonly used oral cancer therapies for patients with prostate cancer, both with potentially high out-of-pocket costs for patients. We investigated the prevalence of financial assistance...
2.
Brown L, Tucker M, Sedhom R, Schwartz E, Zhu J, Kao C, et al.
J Immunother Cancer
. 2021 Mar;
9(3).
PMID: 33653800
Background: Low-density lipoprotein receptor-related protein 1b (encoded by ) is a putative tumor suppressor, and preliminary evidence suggests mutated cancers may have improved outcomes with immune checkpoint inhibitors (ICI). Methods:...
3.
Wu J, Keng V, Patmore D, Kendall J, Patel A, Jousma E, et al.
Cell Rep
. 2016 Feb;
14(8):1979-90.
PMID: 26904939
To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/β-catenin pathway that...
4.
Yan J, Wang Q, Zou K, Wang L, Schwartz E, Fuchs J, et al.
Mol Med Rep
. 2015 Mar;
12(1):498-502.
PMID: 25760445
Osteosarcoma (OS) is the most common type of malignant bone tumor. Despite aggressive multimodal treatments, including surgical resection, chemotherapy and adjunctive immunotherapies, patients with OS with high-grade malignancy have a...
5.
Bill M, Nicholas C, Mace T, Etter J, Li C, Schwartz E, et al.
PLoS One
. 2012 Aug;
7(8):e40724.
PMID: 22899991
The Janus kinase-2 (Jak2)-signal transducer and activator of transcription-3 (STAT3) pathway is critical for promoting an oncogenic and metastatic phenotype in several types of cancer including renal cell carcinoma (RCC)...
6.
Fossey S, Bear M, Lin J, Li C, Schwartz E, Li P, et al.
BMC Cancer
. 2011 Mar;
11:112.
PMID: 21443800
Background: Curcumin is a naturally occurring phenolic compound shown to have a wide variety of antitumor activities; however, it does not attain sufficient blood levels to do so when ingested....
7.
Onimoe G, Liu A, Lin L, Wei C, Schwartz E, Bhasin D, et al.
Invest New Drugs
. 2011 Feb;
30(3):916-26.
PMID: 21340507
Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) is frequently detected in osteosarcoma, and hence, may serve as a therapeutic target. In order to target STAT3, we...
8.
Saradhi U, Ling Y, Wang J, Chiu M, Schwartz E, Fuchs J, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2010 Oct;
878(30):3045-51.
PMID: 20934924
Curcumin and tetrahydrocurcumin (THC) have been found as potent DNMT1 inhibitors, but they suffer from low oral bioavailability and rapid metabolism in vivo. To circumvent these problems, two curcumin analogs:...
9.
Lin L, DeAngelis S, Foust E, Fuchs J, Li C, Li P, et al.
Mol Cancer
. 2010 Aug;
9:217.
PMID: 20712901
Background: Targeting Signal Transducer and Activator of Transcription 3 (STAT3) signaling is an attractive therapeutic approach for most types of human cancers with constitutively activated STAT3. A novel small molecular...
10.
Bill M, Fuchs J, Li C, Yui J, Bakan C, Benson Jr D, et al.
Mol Cancer
. 2010 Jun;
9:165.
PMID: 20576164
Background: We characterized the biologic effects of a novel small molecule STAT3 pathway inhibitor that is derived from the natural product curcumin. We hypothesized this lead compound would specifically inhibit...